The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Katalin Piroska Kiss, Gergely Varga, G. Mikala, Katalin Balassa, Andras Bors, Petra Kovy, Nora Meggyesi, Andras Kozma, Otto Csacsovszki, Peter Remenyi, Istvan Valyi-Nagy, A. Tordai, T. Masszi, H. Andrikovics

Research output: Article

Abstract

Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the treatment applied. Among patients treated with non-proteasome inhibitor (PI)-based therapy, carriership of the minor allele was significantly associated with adverse overall survival (p=.022). In contrast, the adverse effect was overcome by the application of PI-containing treatment (p=.048). Multivariate analyses revealed the independent adverse effect of rs72773978 on survival in the non-PI-treated group (p=.045), but not in PI treatment (OS: p=.093). We confirmed the adverse prognostic effect of rs72773978 associated with non-PI-based treatment regimens. Our results point to the importance of genotypic prognostic information associated with complex clinical background MM.

Original languageEnglish
Pages (from-to)710-716
Number of pages7
JournalLeukemia and Lymphoma
Volume59
Issue number3
DOIs
Publication statusPublished - márc. 4 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this